Back to the Top
Hello everybody,
we are analysing the plasma concentration of drugs from PK
studies, in order to increase the throughtput and to get only the
exposure(AUC) data, can we pool the plasma samples from different
time points and get the AUC(0-t).
For ex: If we have 10 time points and 3 animals per timepoint,
instead of analysing 30 samples, it will be 3 samples. Is that ok?
what are the main advantages and disadvantages in this case? have
anyone has come across any publication regarding this, if so can i
get the detailed information regarding this. The information will
be very helpful.
Thanks,
B.L.Suresh
[Interesting...there were a couple of papers (5 years ago ??)
describing a technique of continuously removing blood slowly over the
sampling period, mix, assay, multiply by time = AUC. In the present
case my guess is that samples of equal volume would need to be
collected at uniform time interval (e.g. every ten minutes). Maybe
adjusting sample size by sample time interval would work...hmmm time
for some math/simulations - db]
Back to the Top
Dear Suresh,
There is a variant scheme which is followed to increase the
throughput. The following reference which uses a scheme of sample
pooling to increase the throughput of 6 propreitary dopamine D4
antagonists should be of help.
Sample Pooling to expedite bioanalysis and pharmacokinetic research.
Be-Sheng Kuo, Ted Van Noord, M. Rose Feng, D. Scott Wright. Journal
of Pharmaceutical and Biomedical Analysis 16 (1998) 837-846.
For ex: If we have 10 time points and 3 animals per
timepoint,instead of analysing 30 samples, it will be 3 samples. Is
that ok?
Instead of vertical pooling of the samples as you have suggested,
pooling of the the samples obtained for the same time point from
different rats leaves you with 10 samples to analyze instead of 30
samples.
Advantages:
* C vs t profile can be obtained from which AUC can be calculated.
* Cmax can also be obtained.
Disadvantages
* Variability in the data is lost, this would be of major concern in
case of drugs with variable bioavailability.Same would be the case
for Cmax also.
regards
Raj
Rajanikanth.M, SRF
Pharmacokinetics & Metabolism Division
Central Drug Research Institute,
LUCKNOW, India.
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)